Jan. 23, 2007 — A comprehensive, large-scale computer simulation of cholesterol regulation, atherogenesis, and cardiovascular risk has been created by Entelos Inc, a life sciences company that builds predictive computer models of human physiology and "virtual patients" for drug discovery and development
The Cardiovascular PhysioLab platform enables Entelos to rapidly assess novel drug targets, evaluate combination therapies, identify and interpret biomarker patterns, and predict a drug's long-term clinical efficacy in managing cholesterol, atherosclerosis and heart disease.
The company says it is currently conducting research in partnership with three big pharmaceutical customers using this platform.
Offering pharmaceutical researchers a dynamic “flight simulator,” the model was developed to support drug discovery research, biomarker identification, and clinical development of cholesterol-lowering and anti-inflammatory therapies that could treat and ultimately prevent atherosclerotic plaque formation — plaque in the arteries is the underlying cause in heart disease and stroke.
PhysioLab will provide in silico (in a computer) modeling of how the effects of multiple interacting factors, particularly lipid levels and inflammatory processes, can contribute to the risk of cardiovascular events.
For more information visit www.entelos.com.